Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BrightSpring Health Services (BTSG) Cash & Equivalents (2023 - 2025)

BrightSpring Health Services (BTSG) has disclosed Cash & Equivalents for 3 consecutive years, with $88.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 44.98% year-over-year to $88.4 million, compared with a TTM value of $88.4 million through Dec 2025, up 44.98%, and an annual FY2025 reading of $88.4 million, up 44.98% over the prior year.
  • Cash & Equivalents was $88.4 million for Q4 2025 at BrightSpring Health Services, down from $140.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $140.3 million in Q3 2025 and bottomed at $13.1 million in Q4 2023.
  • Average Cash & Equivalents over 3 years is $60.5 million, with a median of $58.0 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents soared 366.33% in 2024, then dropped 9.82% in 2025.
  • Year by year, Cash & Equivalents stood at $13.1 million in 2023, then skyrocketed by 366.33% to $61.0 million in 2024, then surged by 44.98% to $88.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for BTSG at $88.4 million in Q4 2025, $140.3 million in Q3 2025, and $70.1 million in Q2 2025.